- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Royal Bank Of Canada Reiterates 'Outperform' Rating on Johnson & Johnson
Analysts see continued strength in pharmaceutical and medical device businesses
Apr. 2, 2026 at 7:36am
Got story updates? Submit your updates here. ›
Royal Bank Of Canada has reissued its 'outperform' rating on shares of Johnson & Johnson (NYSE:JNJ), maintaining a $255 price target on the stock. The analysts cited the company's strong performance across its pharmaceutical and medical device divisions as reasons for their positive outlook.
Why it matters
Johnson & Johnson is one of the world's largest and most diversified healthcare companies, with a portfolio spanning pharmaceuticals, medical devices, and consumer products. As a bellwether for the industry, the company's financial performance and analyst ratings provide insights into the broader healthcare sector.
The details
In their research report, the Royal Bank Of Canada analysts highlighted Johnson & Johnson's robust product pipeline and market-leading positions in key therapeutic areas like immunology, infectious disease, oncology, and neuroscience. They also noted the company's strong balance sheet and history of reliable dividend payments as additional factors supporting their 'outperform' rating.
- The research report was issued on Monday, April 2, 2026.
The players
Johnson & Johnson
A multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of pharmaceutical, medical device, and consumer health products.
Royal Bank Of Canada
A major Canadian financial institution that provides a variety of banking, wealth management, and capital markets services.
What’s next
Investors will be closely watching Johnson & Johnson's upcoming quarterly earnings report to see if the company's performance continues to meet or exceed analyst expectations.
The takeaway
Johnson & Johnson's diversified healthcare business model and strong product pipeline have helped the company maintain a positive outlook from Wall Street analysts, even as the broader pharmaceutical industry faces headwinds from pricing pressures and regulatory changes.
